Candel Therapeutics has recently announced significant strides in both its financial health and the development of its leading cancer immunotherapy. The company is aggressively pursuing the commercialization of its flagship therapy, backed by strategic financing and promising advancements in clinical trials for various cancer types.
Empowering Innovation: Candel Therapeutics' Dual Triumph in Finance and Cancer Research
Strategic Financial Reinforcement to Accelerate Therapeutic Development
Candel Therapeutics has substantially enhanced its financial foundation, reporting robust financial outcomes for the fourth quarter and the entirety of 2025. This fiscal fortification is crucial for propelling its cutting-edge cancer immunotherapy towards commercial viability. The company's CEO, Paul Peter Tak, highlighted the considerable progress across its clinical portfolio and pre-commercialization efforts, setting an optimistic trajectory for 2026 driven by promising catalysts.
Advancing Flagship Immunotherapy: Milestones in Lung and Prostate Cancer Treatment
The biopharmaceutical firm has unveiled plans to launch a pivotal Phase 3 clinical trial for its premier candidate, aglatimagene besadenovec (CAN-2409), in the second quarter of 2026. This trial will focus on patients battling progressive metastatic non-squamous non-small cell lung cancer (NSCLC) who have not responded to prior immune checkpoint inhibitor therapies. Furthermore, Candel intends to submit a Biologics License Application (BLA) for the same therapy in localized intermediate- to high-risk prostate cancer by the fourth quarter of 2026.
Regulatory Progress and Preparations for Market Entry
Candel is meticulously preparing for the potential regulatory submission of aglatimagene for prostate cancer. This involves comprehensive work on chemistry, manufacturing, and controls, alongside the compilation of clinical study reports and other essential BLA components. The second quarter of 2026 is expected to bring updated clinical data from the Phase 3 prostate cancer trial, with biomarker data to follow in the third quarter. The US Food and Drug Administration (FDA) has already recognized aglatimagene's potential by granting it Fast Track and Regenerative Medicine Advanced Therapy designations for localized prostate cancer, as well as Fast Track designation for NSCLC.
Continued Progression in Lung Cancer Research and Emerging Therapies
Following a successful end-of-Phase 2 meeting with the FDA in July 2025, Candel is gearing up for the Phase 3 trial in NSCLC. Early 2026 will see the release of updated survival data from a Phase 2a trial involving stage III or IV NSCLC patients who experienced progression despite immune checkpoint inhibitor treatment. Concurrently, the company is moving forward with linoserpaturev (CAN-3110), a novel therapy for recurrent high-grade glioma. The FDA's approval of an investigational new drug application for CAN-3110 in the first quarter of 2026 paves the way for future randomized Phase 2 development.
Strategic Prioritization and Financial Growth
In a strategic decision, Candel has chosen to pause the development of aglatimagene for pancreatic cancer to dedicate resources to its prostate cancer and NSCLC initiatives, despite promising initial data. Financially, the company significantly bolstered its reserves through various initiatives, including a $100 million gross proceeds from an equity offering in February 2026 and a $130 million term loan facility with Trinity Capital. An additional $100 million royalty funding agreement with RTW Investments, contingent on FDA approval for aglatimagene in prostate cancer, further strengthens its financial outlook.
Operational Expenditures and Future Outlook
Research and development expenses for the fourth quarter of 2025 surged to $11 million, up from $4.8 million in the corresponding period of 2024, primarily due to increased manufacturing, clinical trial, and regulatory costs for the aglatimagene programs. General and administrative expenses also saw an increase, reaching $4.7 million in the fourth quarter of 2025. Despite these expenses, the company reported a narrowed net loss for the full year 2025, largely benefiting from adjustments in the fair value of warrant liabilities. Candel concluded 2025 with $119.7 million in cash and equivalents, projecting that its current liquidity, along with proceeds from the February 2026 equity offering, will sustain operations into the first quarter of 2028, encompassing preparations for aglatimagene's potential commercial launch in 2027.
